Cargando…
Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
BACKGROUND: Polygenic risk scores (PRS), which offer information about genomic risk for common diseases, have been proposed for clinical implementation. The ways in which PRS information may influence a patient’s health trajectory depend on how both the patient and their primary care provider (PCP)...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540716/ https://www.ncbi.nlm.nih.gov/pubmed/36207733 http://dx.doi.org/10.1186/s13073-022-01117-8 |
_version_ | 1784803765711273984 |
---|---|
author | Lewis, Anna C. F. Perez, Emma F. Prince, Anya E. R. Flaxman, Hana R. Gomez, Lizbeth Brockman, Deanna G. Chandler, Paulette D. Kerman, Benjamin J. Lebo, Matthew S. Smoller, Jordan W. Weiss, Scott T. Blout Zawatksy, Carrie L. Meigs, James B. Green, Robert C. Vassy, Jason L. Karlson, Elizabeth W. |
author_facet | Lewis, Anna C. F. Perez, Emma F. Prince, Anya E. R. Flaxman, Hana R. Gomez, Lizbeth Brockman, Deanna G. Chandler, Paulette D. Kerman, Benjamin J. Lebo, Matthew S. Smoller, Jordan W. Weiss, Scott T. Blout Zawatksy, Carrie L. Meigs, James B. Green, Robert C. Vassy, Jason L. Karlson, Elizabeth W. |
author_sort | Lewis, Anna C. F. |
collection | PubMed |
description | BACKGROUND: Polygenic risk scores (PRS), which offer information about genomic risk for common diseases, have been proposed for clinical implementation. The ways in which PRS information may influence a patient’s health trajectory depend on how both the patient and their primary care provider (PCP) interpret and act on PRS information. We aimed to probe patient and PCP responses to PRS clinical reporting choices METHODS: Qualitative semi-structured interviews of both patients (N=25) and PCPs (N=21) exploring responses to mock PRS clinical reports of two different designs: binary and continuous representations of PRS. RESULTS: Many patients did not understand the numbers representing risk, with high numeracy patients being the exception. However, all the patients still understood a key takeaway that they should ask their PCP about actions to lower their disease risk. PCPs described a diverse range of heuristics they would use to interpret and act on PRS information. Three separate use cases for PRS emerged: to aid in gray-area clinical decision-making, to encourage patients to do what PCPs think patients should be doing anyway (such as exercising regularly), and to identify previously unrecognized high-risk patients. PCPs indicated that receiving “below average risk” information could be both beneficial and potentially harmful, depending on the use case. For “increased risk” patients, PCPs were favorable towards integrating PRS information into their practice, though some would only act in the presence of evidence-based guidelines. PCPs describe the report as more than a way to convey information, viewing it as something to structure the whole interaction with the patient. Both patients and PCPs preferred the continuous over the binary representation of PRS (23/25 and 17/21, respectively). We offer recommendations for the developers of PRS to consider for PRS clinical report design in the light of these patient and PCP viewpoints. CONCLUSIONS: PCPs saw PRS information as a natural extension of their current practice. The most pressing gap for PRS implementation is evidence for clinical utility. Careful clinical report design can help ensure that benefits are realized and harms are minimized. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-022-01117-8. |
format | Online Article Text |
id | pubmed-9540716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95407162022-10-08 Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization Lewis, Anna C. F. Perez, Emma F. Prince, Anya E. R. Flaxman, Hana R. Gomez, Lizbeth Brockman, Deanna G. Chandler, Paulette D. Kerman, Benjamin J. Lebo, Matthew S. Smoller, Jordan W. Weiss, Scott T. Blout Zawatksy, Carrie L. Meigs, James B. Green, Robert C. Vassy, Jason L. Karlson, Elizabeth W. Genome Med Research BACKGROUND: Polygenic risk scores (PRS), which offer information about genomic risk for common diseases, have been proposed for clinical implementation. The ways in which PRS information may influence a patient’s health trajectory depend on how both the patient and their primary care provider (PCP) interpret and act on PRS information. We aimed to probe patient and PCP responses to PRS clinical reporting choices METHODS: Qualitative semi-structured interviews of both patients (N=25) and PCPs (N=21) exploring responses to mock PRS clinical reports of two different designs: binary and continuous representations of PRS. RESULTS: Many patients did not understand the numbers representing risk, with high numeracy patients being the exception. However, all the patients still understood a key takeaway that they should ask their PCP about actions to lower their disease risk. PCPs described a diverse range of heuristics they would use to interpret and act on PRS information. Three separate use cases for PRS emerged: to aid in gray-area clinical decision-making, to encourage patients to do what PCPs think patients should be doing anyway (such as exercising regularly), and to identify previously unrecognized high-risk patients. PCPs indicated that receiving “below average risk” information could be both beneficial and potentially harmful, depending on the use case. For “increased risk” patients, PCPs were favorable towards integrating PRS information into their practice, though some would only act in the presence of evidence-based guidelines. PCPs describe the report as more than a way to convey information, viewing it as something to structure the whole interaction with the patient. Both patients and PCPs preferred the continuous over the binary representation of PRS (23/25 and 17/21, respectively). We offer recommendations for the developers of PRS to consider for PRS clinical report design in the light of these patient and PCP viewpoints. CONCLUSIONS: PCPs saw PRS information as a natural extension of their current practice. The most pressing gap for PRS implementation is evidence for clinical utility. Careful clinical report design can help ensure that benefits are realized and harms are minimized. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-022-01117-8. BioMed Central 2022-10-07 /pmc/articles/PMC9540716/ /pubmed/36207733 http://dx.doi.org/10.1186/s13073-022-01117-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lewis, Anna C. F. Perez, Emma F. Prince, Anya E. R. Flaxman, Hana R. Gomez, Lizbeth Brockman, Deanna G. Chandler, Paulette D. Kerman, Benjamin J. Lebo, Matthew S. Smoller, Jordan W. Weiss, Scott T. Blout Zawatksy, Carrie L. Meigs, James B. Green, Robert C. Vassy, Jason L. Karlson, Elizabeth W. Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization |
title | Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization |
title_full | Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization |
title_fullStr | Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization |
title_full_unstemmed | Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization |
title_short | Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization |
title_sort | patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540716/ https://www.ncbi.nlm.nih.gov/pubmed/36207733 http://dx.doi.org/10.1186/s13073-022-01117-8 |
work_keys_str_mv | AT lewisannacf patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT perezemmaf patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT princeanyaer patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT flaxmanhanar patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT gomezlizbeth patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT brockmandeannag patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT chandlerpauletted patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT kermanbenjaminj patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT lebomatthews patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT smollerjordanw patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT weissscottt patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT bloutzawatksycarriel patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT meigsjamesb patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT greenrobertc patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT vassyjasonl patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization AT karlsonelizabethw patientandproviderperspectivesonpolygenicriskscoresimplicationsforclinicalreportingandutilization |